Trial Profile

A Phase I Study of Moxetumomab Pasudotox-tdfk (Lumoxiti (TM)) and Either Rituximab (Rituxan (R)) or Ruxience for Relapsed Hairy Cell Leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Moxetumomab pasudotox (Primary) ; Rituximab (Primary) ; Dexamethasone; Diphenhydramine; Famotidine; Paracetamol
Indications Hairy cell leukaemia
Focus Adverse reactions

Most Recent Events

04 Jun 2024 Results assessing Effect of rituximab on remissions without minimal residual disease and immunogenicity in patients with relapsed/refractory hairy cell leukemia presented at the 60th Annual Meeting of the American Society of Clinical Oncology
12 Jan 2023 Status changed from recruiting to active, no longer recruiting.
07 Oct 2022 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com